2025.07.30本文字数:1075,阅读时长大约2.7分钟导读:7月29日财报出炉:阿斯利康连砍3条细胞疗法管线,却10亿美元押注新平台,细胞疗法版图重构。7月29日,阿斯利康在二季度财报里宣布,对旗下多条细胞疗法管线进行战略梳理,砍掉或按下暂停键若干项目,以聚焦资源。首当其冲的,是Neogene Therapeutics 的 TCR 候选药 NT-125,其 I 期试验被正式叫停。这款疗法...
Source Link2025.07.30本文字数:1075,阅读时长大约2.7分钟导读:7月29日财报出炉:阿斯利康连砍3条细胞疗法管线,却10亿美元押注新平台,细胞疗法版图重构。7月29日,阿斯利康在二季度财报里宣布,对旗下多条细胞疗法管线进行战略梳理,砍掉或按下暂停键若干项目,以聚焦资源。首当其冲的,是Neogene Therapeutics 的 TCR 候选药 NT-125,其 I 期试验被正式叫停。这款疗法...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.